Published in Fam Cancer on January 01, 2016
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (1994) 8.04
A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med (1997) 6.73
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology (1996) 3.54
Psychological and behavioral implications of abnormal mammograms. Ann Intern Med (1991) 3.40
The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology (2008) 3.35
Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet (1997) 3.34
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst (2009) 2.56
Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res (1997) 2.28
Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer (2012) 2.15
Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet (2009) 2.05
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol (2009) 1.92
Cancer family "G" revisited: 1895-1970. Cancer (1971) 1.81
Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA (1999) 1.61
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer (2005) 1.58
Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat (2013) 1.55
How families communicate about HNPCC genetic testing: findings from a qualitative study. Am J Med Genet C Semin Med Genet (2003) 1.54
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer (2000) 1.49
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet (2010) 1.30
Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin (2006) 1.29
The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP. Clin Genet (2007) 1.27
Colorectal cancer survivors undergoing genetic testing for hereditary non-polyposis colorectal cancer: motivational factors and psychosocial functioning. Clin Genet (2007) 1.25
Experiences of genetic risk: disclosure and the gendering of responsibility. Bioethics (2001) 1.25
Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch Syndrome. Fam Cancer (2011) 1.23
Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol (2008) 1.20
Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology (2009) 1.18
Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol (2013) 1.16
Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study. Fam Cancer (2005) 1.15
Hereditary nonpolyposis colorectal cancer family members' perceptions about the duty to inform and health professionals' role in disseminating genetic information. Genet Test (2005) 1.05
Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genet Test (2004) 1.03
Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk. Cancer (2008) 1.01
Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet (2007) 0.97
Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract (2009) 0.91
Psychosocial consequences of predictive genetic testing for Lynch syndrome and associations to surveillance behaviour in a 7-year follow-up study. Fam Cancer (2013) 0.84
High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation. Gastroenterology (2011) 0.81
Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists. Fam Cancer (2013) 0.81
Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models. Hered Cancer Clin Pract (2009) 0.78
Hereditary melanoma and predictive genetic testing: why not? Psychooncology (2005) 0.78
Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genet Med (2016) 0.76
Hereditary Factors in Esophageal Adenocarcinoma. Gastrointest Tumors (2014) 0.75